NCT06577779View on ClinicalTrials.gov

An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

January 31, 2026

Conditions

Attention-deficit/Hyperactivity Disorder

Interventions

DRUG

Methylphenidate Hydrochloride Extended Release Capsule

Subjects will start at dose of 40mg (DR/ER-MPH) day with titrations of 20mg leading to a maximum dose of 100mg (DR/ER-MPH).

Trial Locations (1)

10016

RECRUITING

NYU Langone Health, New York

All Listed Sponsors

lead

NYU Langone Health

OTHER

NCT06577779 - An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening | Biotech Hunter | Biotech Hunter